EP1303280A4 - Enhanced brain function by gaba-ergic stimulation - Google Patents

Enhanced brain function by gaba-ergic stimulation

Info

Publication number
EP1303280A4
EP1303280A4 EP01946582A EP01946582A EP1303280A4 EP 1303280 A4 EP1303280 A4 EP 1303280A4 EP 01946582 A EP01946582 A EP 01946582A EP 01946582 A EP01946582 A EP 01946582A EP 1303280 A4 EP1303280 A4 EP 1303280A4
Authority
EP
European Patent Office
Prior art keywords
ergic
gaba
stimulation
brain function
enhanced brain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01946582A
Other languages
German (de)
French (fr)
Other versions
EP1303280A1 (en
Inventor
Audie G Leventhal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Utah Research Foundation UURF
Original Assignee
University of Utah Research Foundation UURF
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Utah Research Foundation UURF filed Critical University of Utah Research Foundation UURF
Publication of EP1303280A1 publication Critical patent/EP1303280A1/en
Publication of EP1303280A4 publication Critical patent/EP1303280A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP01946582A 2000-06-23 2001-06-20 Enhanced brain function by gaba-ergic stimulation Withdrawn EP1303280A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US21338800P 2000-06-23 2000-06-23
US213388P 2000-06-23
US27742701P 2001-03-20 2001-03-20
US277427P 2001-03-20
PCT/US2001/019719 WO2002000221A1 (en) 2000-06-23 2001-06-20 Enhanced brain function by gaba-ergic stimulation

Publications (2)

Publication Number Publication Date
EP1303280A1 EP1303280A1 (en) 2003-04-23
EP1303280A4 true EP1303280A4 (en) 2005-09-21

Family

ID=26908032

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01946582A Withdrawn EP1303280A4 (en) 2000-06-23 2001-06-20 Enhanced brain function by gaba-ergic stimulation

Country Status (4)

Country Link
EP (1) EP1303280A4 (en)
AU (3) AU6860901A (en)
CA (1) CA2413405A1 (en)
WO (1) WO2002000221A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009016329A1 (en) * 2007-07-31 2009-02-05 Cambridge Enterprise Limited Use of gabaa receptor antagonists to treat cognitive impairment in patients with psychiatric conditions
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999062899A1 (en) * 1998-06-04 1999-12-09 Merck Sharp & Dohme Limited Tetrahydroindolone derivatives as gabaaalpha5 ligands for enhancing cognition
WO2000027849A2 (en) * 1998-11-12 2000-05-18 Merck & Co., Inc. Therapeutic polymorphs of a gaba-a alpha-5 inverse agonist and pamoate formulations of the same
WO2000027382A2 (en) * 1998-11-12 2000-05-18 Merck & Co., Inc. Combination of a gaba-a alpha 5 inverse agonist and cox-2 inhibitor, nsaid, estrogen or vitamin e
WO2000029412A1 (en) * 1998-11-12 2000-05-25 Merck Sharp & Dohme Limited PENTAAZA-CYCLOPENTA[A]NAPHTHALENE DERIVATIVES AS LIGANDS FOR GABAA α5 RECEPTORS
WO2000077008A2 (en) * 1999-06-15 2000-12-21 Neurogen Corporation Heteroaryl substituted piperidines as gaba brain receptor lingands

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3397209A (en) * 1966-11-25 1968-08-13 Geigy Chem Corp 3-hydroxy-5-isoxazole-carboxamide
US5958933A (en) * 1982-11-23 1999-09-28 Naftchi; N. Eric Neurologically active compounds and compounds with multiple activities

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999062899A1 (en) * 1998-06-04 1999-12-09 Merck Sharp & Dohme Limited Tetrahydroindolone derivatives as gabaaalpha5 ligands for enhancing cognition
WO2000027849A2 (en) * 1998-11-12 2000-05-18 Merck & Co., Inc. Therapeutic polymorphs of a gaba-a alpha-5 inverse agonist and pamoate formulations of the same
WO2000027382A2 (en) * 1998-11-12 2000-05-18 Merck & Co., Inc. Combination of a gaba-a alpha 5 inverse agonist and cox-2 inhibitor, nsaid, estrogen or vitamin e
WO2000029412A1 (en) * 1998-11-12 2000-05-25 Merck Sharp & Dohme Limited PENTAAZA-CYCLOPENTA[A]NAPHTHALENE DERIVATIVES AS LIGANDS FOR GABAA α5 RECEPTORS
WO2000077008A2 (en) * 1999-06-15 2000-12-21 Neurogen Corporation Heteroaryl substituted piperidines as gaba brain receptor lingands

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SCHMOLESKY ET AL: "Degradation of stimulus selectivity of visual cortical cells in senescent rhesus monkeys.", NATURE NEUROSCIENCE, vol. 3, no. 4, 2000 - 2000, pages 384 - 390, XP002335609 *
See also references of WO0200221A1 *

Also Published As

Publication number Publication date
WO2002000221B1 (en) 2002-02-28
CA2413405A1 (en) 2002-01-03
WO2002000221A1 (en) 2002-01-03
AU2001268609B2 (en) 2006-05-11
AU2006203432A1 (en) 2006-08-31
EP1303280A1 (en) 2003-04-23
AU6860901A (en) 2002-01-08

Similar Documents

Publication Publication Date Title
GB0028264D0 (en) Well treatment
GB0028269D0 (en) Well treatment
EP1425066A4 (en) Defibrillators
GB0028429D0 (en) Therapy
PL362855A1 (en) Improved treatment
GB0003556D0 (en) Cochlear implant
GB0030583D0 (en) Nerve regeneration
GB2358194B (en) Electrolytic treatment
GB2379395B (en) Cardiac stimulation apparatus
GB0001710D0 (en) Therapeutic treatment
EP1427478A4 (en) Defibrillators
GB0122746D0 (en) Defibrillator
AU6860901A (en) Enhanced brain function by gaba-ergic stimulation
AU2096002A (en) Therapeutic treatment
EP1279384A4 (en) Erogenic zone stimulator
GB0031321D0 (en) Treatment
GB0014437D0 (en) Immune response stimulation
GB0207931D0 (en) Brain stimulator
GB2405099B (en) Cardiac stimulation apparatus
GB0014548D0 (en) Boiler brain
GB0009482D0 (en) Baby controlled stimulation system
GB0006471D0 (en) Foetal stimulator
CA89815S (en) Electro-medical nerve stimulation apparatus
GB0111047D0 (en) Pacemaker
GB0107878D0 (en) Pacemaker

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030123

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20050809

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20070503